Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,810,742 papers from all fields of science
Search
Sign In
Create Free Account
niraparib
Known as:
2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Niraparib inhibits PARP activity, enhancing the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Broader (3)
Indazoles
Piperidines
Poly(ADP-ribose) Polymerase Inhibitors
Narrower (1)
MK 4827
NCIt Antineoplastic Agent Terminology
PARP1 protein, human
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
R. McQueen
,
M. Whittington
,
Rick Chapman
,
Varun M. Kumar
,
Jonathan D. Campbell
PharmacoEconomics (Auckland)
2019
Corpus ID: 141511740
In the March 2019 issue of Pharmacoeconomics, Guy et al. evaluated the cost effectiveness of niraparib compared with routine…
Expand
2018
2018
Human mass balance and metabolite profiling studies of the new anticancer agents plitidepsin, lurbinectedin and niraparib
L. V. Andel
2018
Corpus ID: 81748249
There is a vast increase in the number of newly developed anticancer therapeutics, of which marine-derived anticancer drugs and…
Expand
2017
2017
953PA phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial…
M. Mirza
,
J. Wang
,
+13 authors
J. Mäenpää
2017
Corpus ID: 206323957
Results: 593 patients were identified from the Edinburgh Ovarian Cancer Database between January 1974 and December 2015. 267…
Expand
2017
2017
FDA approvals for the first 6 months of 2017
Asher Mullard
Nature reviews. Drug discovery
2017
Corpus ID: 20063192
2016
2016
Niraparib Slows Ovarian Cancer Progression.
Cancer Discovery
2016
Corpus ID: 20778005
Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo…
Expand
2016
2016
Cancer model consortium debuts
Asher Mullard
Nature reviews. Drug discovery
2016
Corpus ID: 19997844
2016
2016
Abstract 4353: Preclinical evaluation of the PARP inhibitor niraparib and cytotoxic chemotherapy alone or in combination in a panel of 25 triple-negative breast cancer PDX models: Relevance of BRCA…
O. Deas
,
S. Cairo
,
+4 authors
J. Judde
2016
Corpus ID: 56735618
Poly-ADP-ribose polymerase 1 (PARP) inhibitors are therapeutically effective in a subset of breast and high-grade ovarian cancers…
Expand
2015
2015
Abstract P5-06-04: The PARP inhibitor niraparib demonstrated activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score
Yan Wang
,
S. Cairo
,
+9 authors
K. Wilcoxen
2015
Corpus ID: 70586322
Triple negative breast cancer (TNBC), which comprises 15% of all breast cancers, has a poor prognosis and currently lacks…
Expand
2014
2014
Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum…
K. Moore
,
Zhi-yi Zhang
,
+4 authors
V. Kansra
2014
Corpus ID: 78274130
e16531 Background: Niraparib is an oral, potent PARP1/2 inhibitor that induces synthetic lethality in BRCA1/2 deficient and…
Expand
2014
2014
Phase III setback for lead angiopoietin inhibitor
Asher Mullard
Nature reviews. Drug discovery
2014
Corpus ID: 43701362
(Lancet Oncol. 15, 852–861; 2014). At an interim analysis, overall survival did not differ between treatment groups. The most…
Expand